REG - IXICO plc - Contract Win

IXICOAnnouncement

23/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240523:nRSW5396Pa&default-theme=true

RNS Number : 5396P  IXICO plc  23 May 2024

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the UK version of the EU
Market Abuse Regulation 596/2014 which is part of UK law by virtue of the
European Union (Withdrawal) Act 2018, as amended and supplemented from time to
time. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

 

23 May 2024

IXICO plc

("IXICO" or the "Company")

 

Alzheimer's Disease (AD) trial contract win.

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience announces that it has signed a contract
with the Global Alzheimer's Platform Foundation® ("GAP") to support GAP's
planned Bio-Hermes 2 trial. The contract value is worth over £1 million over
a 48-month term. The Company does not expect to adjust its expectations of
performance for the financial year ending 30 September 2024 ("FY24") following
the receipt of this contract.

 

In the Bio-Hermes 2 trial, IXICO will apply its expertise to qualify
approximately 30 participating imaging centres for the collection of amyloid
PET and tau PET molecular imaging and MR Imaging scans from approximately
1,200 volunteers over the age of 60. The volunteers will be screened for
Preclinical Alzheimer's Disease, Prodromal AD, or Mild Dementia AD, with IXICO
providing both visual read and AI driven quantitative analysis across all
three imaging modalities used in the Bio-Hermes 2 trial.

 

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"We are delighted to deepen our long-term strategic partnership with GAP by
building on the success of the initial Bio-Hermes trial to now also be
selected to deliver all of the imaging analysis requirements of the Bio-Hermes
2 trial across both MRI and PET. With the significant unmet medical need for
new therapies in Alzheimer's Disease, we are excited about the prospects of
deepening our collaboration with GAP in support of the success of the
Bio-Hermes 2 trial."

 

 

John Dwyer, President of Global Alzheimer's Platform Foundation (GAP),
commented:

"Our collaboration with IXICO for neuroimaging and AI driven quantitative
analysis is a fundamental element of GAP's innovative Bio-Hermes 2 trial,
which is taking a novel approach to incorporate a broad set of digital and
blood biomarker results for comparison across cognitively normal and impaired
individuals. We've also committed to an unprecedented level of participation
by traditionally underrepresented populations in AD studies so that the
insights generated by BH2 will benefit everyone impacted by Alzheimer's and
related dementias."

 

 

For further information please contact:

 

 IXICO plc                                                                         +44 (0) 20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and                          +44 (0) 20 7220 0500

 Sole Broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

 

 

About IXICO

 

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.ixico.com/)  and
follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUUSNRSUUVUAR